Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Vaccines

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 276 articles:
HTML format



Single Articles


    July 2024
  1. SALMON DA, Orenstein WA, Plotkin SA, Chen RT, et al
    Funding Postauthorization Vaccine-Safety Science.
    N Engl J Med. 2024;391:102-105.
    PubMed    


    June 2024

  2. Are We Prepared for Bird Flu?: ITT Episode 32.
    N Engl J Med. 2024;390:e59.
    PubMed    


    May 2024
  3. LIN DY, Du Y, Xu Y, Paritala S, et al
    Durability of XBB.1.5 Vaccines against Omicron Subvariants.
    N Engl J Med. 2024 May 29. doi: 10.1056/NEJMc2402779.
    PubMed    


  4. RUBIN EJ, Baden LR, Marrazzo J, Monto A, et al
    Audio Interview: The Current State of Avian Influenza.
    N Engl J Med. 2024 May 20. doi: 10.1056/NEJMe2406223.
    PubMed    


  5. WANG JJ, Schonborn L, Warkentin TE, Chataway T, et al
    Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.
    N Engl J Med. 2024;390:1827-1829.
    PubMed    


    April 2024
  6. HAMMOND J, Fountaine RJ, Yunis C, Fleishaker D, et al
    Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
    N Engl J Med. 2024;390:1186-1195.
    PubMed     Abstract available


    March 2024
  7. HSIAO A, Fireman B, Klein NP
    Recombinant Influenza Vaccine in Adults under 65 Years of Age. Reply.
    N Engl J Med. 2024;390:1156.
    PubMed    


  8. WOO EJ, Hulse AN
    Recombinant Influenza Vaccine in Adults under 65 Years of Age.
    N Engl J Med. 2024;390:1155-1156.
    PubMed    


  9. HAVIARI S, Massonnaud CR, Dupont A
    Recombinant Influenza Vaccine in Adults under 65 Years of Age.
    N Engl J Med. 2024;390:1155.
    PubMed    


  10. RASMUSSEN SA, Jamieson DJ
    Maternal RSV Vaccine - Weighing Benefits and Risks.
    N Engl J Med. 2024;390:1050-1051.
    PubMed    


  11. DIEUSSAERT I, Hyung Kim J, Luik S, Seidl C, et al
    RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.
    N Engl J Med. 2024;390:1009-1021.
    PubMed     Abstract available


    February 2024
  12. MONTO AS, Zambon M, Weir JP
    The End of B/Yamagata Influenza Transmission - Transitioning from Quadrivalent Vaccines.
    N Engl J Med. 2024 Feb 28. doi: 10.1056/NEJMp2314801.
    PubMed    



  13. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2024;390:772.
    PubMed    


  14. HIGGINS DM, O'Leary ST
    The Risks of Normalizing Parental Vaccine Hesitancy.
    N Engl J Med. 2024;390:485-487.
    PubMed    


  15. HALSTEAD SB
    Three Dengue Vaccines - What Now?
    N Engl J Med. 2024;390:464-465.
    PubMed    


  16. KALLAS EG, Cintra MAT, Moreira JA, Patino EG, et al
    Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults.
    N Engl J Med. 2024;390:397-408.
    PubMed     Abstract available


    December 2023
  17. KOTTKAMP AC, Samanovic MI, Duerr R, Oom AL, et al
    Antibody Titers against Mpox Virus after Vaccination.
    N Engl J Med. 2023;389:2299-2301.
    PubMed    


  18. HSIAO A, Yee A, Fireman B, Hansen J, et al
    Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age.
    N Engl J Med. 2023;389:2245-2255.
    PubMed     Abstract available


  19. WILSON E, Goswami J, Baqui AH, Doreski PA, et al
    Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
    N Engl J Med. 2023;389:2233-2244.
    PubMed     Abstract available


  20. COHN AC, Hall AJ
    Continued Progress in the Development of Safe and Effective RSV Immunizations.
    N Engl J Med. 2023;389:2289-2290.
    PubMed    


    October 2023
  21. DEPUTY NP, Gerhart JL, Feldstein LR
    Vaccine Effectiveness against Mpox in the United States. Reply.
    N Engl J Med. 2023;389:1440-1441.
    PubMed    


  22. ARBEL R, Zucker R, Wolff-Sagy Y
    Vaccine Effectiveness against Mpox in the United States.
    N Engl J Med. 2023;389:1440.
    PubMed    


    September 2023
  23. TITANJI BK, Eick-Cost A, Partan ES, Epstein L, et al
    Effectiveness of Smallpox Vaccination to Prevent Mpox in Military Personnel.
    N Engl J Med. 2023;389:1147-1148.
    PubMed    


  24. KARRON RA
    Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. Reply.
    N Engl J Med. 2023;389:1055.
    PubMed    


  25. KAMPMANN B, Radley D, Munjal I
    Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. Reply.
    N Engl J Med. 2023;389:1053-1055.
    PubMed    


  26. BUONSENSO D
    Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
    N Engl J Med. 2023;389:1053.
    PubMed    


  27. ALLELY D, Prasad V
    Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
    N Engl J Med. 2023;389:1052-1053.
    PubMed    


    August 2023
  28. LO NC, Gonsalves GS
    Outbreaks in U.S. Migrant Detention Centers - A Vaccine-Preventable Cause of Health Inequity.
    N Engl J Med. 2023;389:679-681.
    PubMed    


  29. CLARKE E, Alderson MR, Tapia MD
    Meningococcal Vaccine in Mali and Gambia. Reply.
    N Engl J Med. 2023;389:577-578.
    PubMed    


  30. GRIFFIN DWJ, Hoy JF, McMahon JH
    Meningococcal Vaccine in Mali and Gambia.
    N Engl J Med. 2023;389:577.
    PubMed    


  31. WARKENTIN TE, Baskin-Miller J, Raybould AL, Sheppard JI, et al
    Adenovirus-Associated Thrombocytopenia, Thrombosis, and VITT-like Antibodies.
    N Engl J Med. 2023;389:574-577.
    PubMed    


    July 2023
  32. ARBEL R, Sergienko R, Netzer D, Hammerman A, et al
    Potential "Healthy Vaccinee Bias" in a Study of BNT162b2 Vaccine against Covid-19. Reply.
    N Engl J Med. 2023;389:285-286.
    PubMed    


  33. HOEG TB, Duriseti R, Prasad V
    Potential "Healthy Vaccinee Bias" in a Study of BNT162b2 Vaccine against Covid-19.
    N Engl J Med. 2023;389:284-285.
    PubMed    


  34. BAKER CJ
    Group B Streptococcal Vaccine - Sisyphus Reconciled.
    N Engl J Med. 2023;389:275-277.
    PubMed    


  35. MADHI SA, Anderson AS, Absalon J, Radley D, et al
    Potential for Maternally Administered Vaccine for Infant Group B Streptococcus.
    N Engl J Med. 2023;389:215-227.
    PubMed     Abstract available


  36. PITTET LF, Messina NL, Curtis N
    BCG to Protect against Covid-19 in Health Care Workers. Reply.
    N Engl J Med. 2023;389:192.
    PubMed    


  37. BENN CS, Netea MG, Aaby P
    BCG to Protect against Covid-19 in Health Care Workers.
    N Engl J Med. 2023;389:191-192.
    PubMed    


  38. LOPEZ-CAMPOS GH, Valvano MA
    BCG to Protect against Covid-19 in Health Care Workers.
    N Engl J Med. 2023;389:191.
    PubMed    


    June 2023
  39. WALLENDER E, Peacock G, Wharton M, Walensky RP, et al
    Uninsured and Not Immune - Closing the Vaccine-Coverage Gap for Adults.
    N Engl J Med. 2023 Jun 21. doi: 10.1056/NEJMp2306200.
    PubMed    


  40. CASTILLA J, Cenoz MG, Barricarte A
    Meningococcal Group B Vaccine (4CMenB) in Children. Reply.
    N Engl J Med. 2023;388:2109.
    PubMed    


  41. LOPEZ-LACORT M, Munoz-Quiles C, Orrico-Sanchez A
    Meningococcal Group B Vaccine (4CMenB) in Children.
    N Engl J Med. 2023;388:2109.
    PubMed    


    May 2023
  42. HAIDARA FC, Umesi A, Sow SO, Ochoge M, et al
    Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.
    N Engl J Med. 2023;388:1942-1955.
    PubMed     Abstract available


  43. DEPUTY NP, Deckert J, Chard AN, Sandberg N, et al
    Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States.
    N Engl J Med. 2023 May 18. doi: 10.1056/NEJMoa2215201.
    PubMed     Abstract available


  44. MARKOWITZ LE, Unger ER
    Human Papillomavirus Vaccination.
    N Engl J Med. 2023;388:1790-1798.
    PubMed    


  45. GOULD CV, Staples JE, Huang CY, Brault AC, et al
    Combating West Nile Virus Disease - Time to Revisit Vaccination.
    N Engl J Med. 2023;388:1633-1636.
    PubMed    


    April 2023
  46. PITTET LF, Messina NL, Orsini F, Moore CL, et al
    Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.
    N Engl J Med. 2023;388:1582-1596.
    PubMed     Abstract available


  47. KAMPMANN B, Madhi SA, Munjal I, Simoes EAF, et al
    Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
    N Engl J Med. 2023 Apr 5. doi: 10.1056/NEJMoa2216480.
    PubMed     Abstract available


  48. WALSH EE, Perez Marc G, Zareba AM, Falsey AR, et al
    Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
    N Engl J Med. 2023 Apr 5. doi: 10.1056/NEJMoa2213836.
    PubMed     Abstract available


    March 2023
  49. JABAGI MJ, Bertrand M, Botton J, Le Vu S, et al
    Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster.
    N Engl J Med. 2023 Mar 29. doi: 10.1056/NEJMc2302134.
    PubMed    


  50. NEUZIL KM
    An mRNA Influenza Vaccine - Could It Deliver?
    N Engl J Med. 2023;388:1139-1141.
    PubMed    


  51. FREY SE, Goll JB, Beigel JH
    Erythema and Induration after Mpox (JYNNEOS) Vaccination Revisited.
    N Engl J Med. 2023 Mar 22. doi: 10.1056/NEJMc2215846.
    PubMed    


  52. ALVES K, Plested JS, Galbiati S, Chau G, et al
    Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373.
    N Engl J Med. 2023;388:857-859.
    PubMed    


  53. OFFIT PA
    Bivalent Covid-19 Vaccines. Reply.
    N Engl J Med. 2023;388:10.
    PubMed    


  54. MARKS PW, Califf RM
    Bivalent Covid-19 Vaccines.
    N Engl J Med. 2023;388:10.
    PubMed    


  55. LI D, Duan M, Wang X, Gao P, et al
    Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines.
    N Engl J Med. 2023 Mar 1. doi: 10.1056/NEJMc2216233.
    PubMed    


    February 2023

  56. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2023;388:672.
    PubMed    


  57. RUBIN EJ, Baden LR, Graham BS, Morrissey S, et al
    Audio Interview: What to Expect from Covid-19 Vaccines.
    N Engl J Med. 2023;388:e23.
    PubMed    


  58. MUNOZ FM, Sher LD, Sabharwal C, Gurtman A, et al
    Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
    N Engl J Med. 2023;388:621-634.
    PubMed     Abstract available


  59. FALSEY AR, Williams K, Gymnopoulou E, Bart S, et al
    Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
    N Engl J Med. 2023;388:609-620.
    PubMed     Abstract available


  60. PAPI A, Ison MG, Langley JM, Lee DG, et al
    Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
    N Engl J Med. 2023;388:595-608.
    PubMed     Abstract available


  61. GRAHAM BS
    The Journey to RSV Vaccines - Heralding an Era of Structure-Based Design.
    N Engl J Med. 2023;388:579-581.
    PubMed    


  62. HUTH L, Schafer L, Almanzar G, Lupoli G, et al
    Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis.
    N Engl J Med. 2023 Feb 15. doi: 10.1056/NEJMc2216309.
    PubMed    


  63. WITBERG G
    More on Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. Reply.
    N Engl J Med. 2023;388:576.
    PubMed    


  64. TOVANI-PALONE MR, Patil S
    More on Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
    N Engl J Med. 2023;388:576.
    PubMed    


  65. REIS G, Moreira Silva EAS, Medeiros Silva DC, Thabane L, et al
    Early Treatment with Pegylated Interferon Lambda for Covid-19.
    N Engl J Med. 2023;388:518-528.
    PubMed     Abstract available


  66. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Updating and Standardizing Covid-19 Vaccines.
    N Engl J Med. 2023;388:e21.
    PubMed    


  67. CASTILLA J, Garcia Cenoz M, Abad R, Sanchez-Cambronero L, et al
    Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children.
    N Engl J Med. 2023;388:427-438.
    PubMed     Abstract available


    January 2023

  68. Covid Vaccines - Playing the Long Game.
    N Engl J Med. 2023;388:e5.
    PubMed    


  69. ZOU J, Kurhade C, Patel S, Kitchin N, et al
    Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.
    N Engl J Med. 2023 Jan 25. doi: 10.1056/NEJMc2214916.
    PubMed    


  70. WINOKUR P, Gayed J, Fitz-Patrick D, Thomas SJ, et al
    Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
    N Engl J Med. 2023;388:214-227.
    PubMed     Abstract available


  71. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 Vaccines and New Viral Variants.
    N Engl J Med. 2023;388:e8.
    PubMed    


  72. OFFIT PA
    Bivalent Covid-19 Vaccines - A Cautionary Tale.
    N Engl J Med. 2023 Jan 11. doi: 10.1056/NEJMp2215780.
    PubMed    


  73. COLLIER AY, Miller J, Hachmann NP, McMahan K, et al
    Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.
    N Engl J Med. 2023 Jan 11. doi: 10.1056/NEJMc2213948.
    PubMed    


  74. SCHUSTER JE, Hamdan L, Dulek DE, Kitko CL, et al
    Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants.
    N Engl J Med. 2023 Jan 11. doi: 10.1056/NEJMc2210825.
    PubMed    


    December 2022
  75. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Potential Covid Vaccine Strategies.
    N Engl J Med. 2022;387:e75.
    PubMed    


  76. WENZEL RP
    Cholera in Haiti, Again.
    N Engl J Med. 2022;387:2300-2301.
    PubMed    


  77. CHIN ET, Goldhaber-Fiebert JD
    Protection against Omicron from Vaccination and Previous Infection. Reply.
    N Engl J Med. 2022;388:10.
    PubMed    


  78. ZENG J, Szanyi J, Blakely T
    Protection against Omicron from Vaccination and Previous Infection.
    N Engl J Med. 2022;388:10.
    PubMed    


  79. GILBERT PB, Donis RO, Koup RA, Fong Y, et al
    A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines.
    N Engl J Med. 2022;387:2203-2206.
    PubMed    


  80. KIEH M, Richert L, Beavogui AH, Grund B, et al
    Randomized Trial of Vaccines for Zaire Ebola Virus Disease.
    N Engl J Med. 2022 Dec 14. doi: 10.1056/NEJMoa2200072.
    PubMed     Abstract available


  81. THY M, Peiffer-Smadja N, Mailhe M, Kramer L, et al
    Breakthrough Infections after Postexposure Vaccination against Mpox.
    N Engl J Med. 2022 Dec 7. doi: 10.1056/NEJMc2211944.
    PubMed    


    November 2022
  82. CHALKIAS S, Feng J, Chen X, Zhou H, et al
    Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination.
    N Engl J Med. 2022 Nov 23. doi: 10.1056/NEJMc2212772.
    PubMed    


  83. RUBIN EJ, Baden LR, Marks P, Morrissey S, et al
    Audio Interview: The FDA and Covid-19 Vaccines.
    N Engl J Med. 2022;387:e60.
    PubMed    


  84. PALLANSCH MA
    Circulating Poliovirus in New York - New Instance of an Old Problem.
    N Engl J Med. 2022;387:1725-1728.
    PubMed    


  85. CANETTI M, Barda N, Gilboa M, Indenbaum V, et al
    Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose.
    N Engl J Med. 2022 Nov 9. doi: 10.1056/NEJMc2211283.
    PubMed    


  86. CHEMAITELLY H, AlMukdad S, Ayoub HH, Altarawneh HN, et al
    Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
    N Engl J Med. 2022 Nov 2. doi: 10.1056/NEJMoa2210058.
    PubMed     Abstract available


    October 2022
  87. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Assessing the Effect of Vaccination and Prior SARS-CoV-2 Infection.
    N Engl J Med. 2022;387:e50.
    PubMed    


  88. CHIN ET, Leidner D, Lamson L, Lucas K, et al
    Protection against Omicron from Vaccination and Previous Infection in a Prison System.
    N Engl J Med. 2022 Oct 26. doi: 10.1056/NEJMoa2207082.
    PubMed     Abstract available


  89. ANDERSON EJ, Creech CB, Berthaud V, Piramzadian A, et al
    Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
    N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMoa2209367.
    PubMed     Abstract available


  90. WITBERG G, Magen O, Hoss S, Talmor-Barkan Y, et al
    Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
    N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMc2207270.
    PubMed    


  91. RUBIN EJ, Baden LR, Neuzil KM, Morrissey S, et al
    Audio Interview: Developing New Covid-19 Vaccines.
    N Engl J Med. 2022;387:e44.
    PubMed    


    September 2022
  92. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Assessing Bivalent Vaccines against Covid-19.
    N Engl J Med. 2022;387:e37.
    PubMed    


  93. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Can Vaccines Prevent Transmission of Covid-19?
    N Engl J Med. 2022;387:e30.
    PubMed    


  94. THURNER L, Kessel C, Fadle N, Regitz E, et al
    IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination.
    N Engl J Med. 2022 Sep 21. doi: 10.1056/NEJMc2205667.
    PubMed    


  95. CHALKIAS S, Harper C, Vrbicky K, Walsh SR, et al
    A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
    N Engl J Med. 2022 Sep 16. doi: 10.1056/NEJMoa2208343.
    PubMed     Abstract available


  96. LARSON HJ
    The Vaccine-Hesitant Moment. Reply.
    N Engl J Med. 2022;387:1050-1051.
    PubMed    


  97. HOROWITZ ME
    The Vaccine-Hesitant Moment.
    N Engl J Med. 2022;387:1050.
    PubMed    


  98. HERRERA-COMOGLIO R, Lane S
    Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine.
    N Engl J Med. 2022 Sep 14. doi: 10.1056/NEJMc2210813.
    PubMed    


  99. COLLIE S, Nayager J, Bamford L, Bekker LG, et al
    Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa.
    N Engl J Med. 2022 Sep 14. doi: 10.1056/NEJMc2210093.
    PubMed    


  100. SHEN X, Chalkias S, Feng J, Chen X, et al
    Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.
    N Engl J Med. 2022 Sep 9. doi: 10.1056/NEJMc2210648.
    PubMed    


  101. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Rolling Out New Covid-19 Vaccines.
    N Engl J Med. 2022;387:e26.
    PubMed    


  102. QU P, Faraone JN, Evans JP, Zheng YM, et al
    Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2210546.
    PubMed    


  103. LIN DY, Gu Y, Xu Y, Zeng D, et al
    Effects of Vaccination and Previous Infection on Omicron Infections in Children.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2209371.
    PubMed    


    August 2022
  104. BROOKS JT, Marks P, Goldstein RH, Walensky RP, et al
    Intradermal Vaccination for Monkeypox - Benefits for Individual and Public Health.
    N Engl J Med. 2022 Aug 31. doi: 10.1056/NEJMp2211311.
    PubMed    


  105. BAROUCH DH
    Covid-19 Vaccines - Immunity, Variants, Boosters.
    N Engl J Med. 2022 Aug 31. doi: 10.1056/NEJMra2206573.
    PubMed    


  106. BRAMANTE CT, Huling JD, Tignanelli CJ, Buse JB, et al
    Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    N Engl J Med. 2022;387:599-610.
    PubMed     Abstract available


  107. KOHANE I, Omenn GS
    Understanding Covid Vaccine Efficacy over Time - Bridging a Gap Between Public Health and Health Care.
    N Engl J Med. 2022 Aug 6. doi: 10.1056/NEJMp2201084.
    PubMed    


  108. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Updated Covid-19 Vaccines and a Look at Monkeypox.
    N Engl J Med. 2022;387:e16.
    PubMed    


    July 2022
  109. TAN SHX, Cook AR, Heng D, Ong B, et al
    Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.
    N Engl J Med. 2022 Jul 20. doi: 10.1056/NEJMoa2203209.
    PubMed     Abstract available


  110. RUBIN EJ, Baden LR, Marks P, Morrissey S, et al
    Audio Interview: Covid-19 Vaccines and the FDA.
    N Engl J Med. 2022;387:e10.
    PubMed    


  111. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Designing the Next Covid-19 Vaccine.
    N Engl J Med. 2022;387:e6.
    PubMed    


  112. ZHAO X, Zhang R, Qiao S, Wang X, et al
    Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines.
    N Engl J Med. 2022 Jul 6. doi: 10.1056/NEJMc2206900.
    PubMed    


    June 2022
  113. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: How Effective is Covid-19 Vaccination in Children?
    N Engl J Med. 2022;386:e78.
    PubMed    


  114. LARSON HJ, Gakidou E, Murray CJL
    The Vaccine-Hesitant Moment.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMra2106441.
    PubMed    


  115. WAXMAN JG, Magen O, Hernan MA
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine. Reply.
    N Engl J Med. 2022;387.
    PubMed    


  116. TUMMINIA A, Romano M
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine.
    N Engl J Med. 2022;387.
    PubMed    


  117. COHEN-STAVI CJ, Magen O, Barda N, Yaron S, et al
    BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMoa2205011.
    PubMed     Abstract available


  118. LAUNAY O, Cachanado M, Luong Nguyen LB, Ninove L, et al
    Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine.
    N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMc2206711.
    PubMed    


  119. SCHONBORN L, Seck SE, Thiele T, Warkentin TE, et al
    SARS-CoV-2 Infection in Patients with a History of VITT.
    N Engl J Med. 2022 Jun 27. doi: 10.1056/NEJMc2206601.
    PubMed    


  120. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Vaccinating Young Children against Covid-19.
    N Engl J Med. 2022;386:e77.
    PubMed    


  121. SCHMOELE-THOMA B, Zareba AM, Jiang Q, Maddur MS, et al
    Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
    N Engl J Med. 2022;386:2377-2386.
    PubMed     Abstract available


  122. BAR-ON YM, Goldberg Y, Milo R
    Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. Reply.
    N Engl J Med. 2022;386:2441-2442.
    PubMed    


  123. WOHL A, Leibowitz R
    Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
    N Engl J Med. 2022;386:2441.
    PubMed    


  124. DESILVA M, Haapala J, Vazquez-Benitez G, Vesco KK, et al
    Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMc2205276.
    PubMed    


  125. HALASA NB, Olson SM, Staat MA, Newhams MM, et al
    Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMoa2204399.
    PubMed     Abstract available


  126. RASMUSSEN SA, Jamieson DJ
    Covid-19 Vaccination during Pregnancy - Two for the Price of One.
    N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMe2206730.
    PubMed    


  127. PRICE AM, Olson SM, Patel MM
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents. Reply.
    N Engl J Med. 2022;386:2346.
    PubMed    


  128. ZENG G
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    N Engl J Med. 2022;386:2345-2346.
    PubMed    


  129. LEUCHTER RK, Jackson NJ, Mafi JN, Sarkisian CA, et al
    Association between Covid-19 Vaccination and Influenza Vaccination Rates.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMc2204560.
    PubMed    


  130. HOPKINS S, Hall V, Klenerman P
    Protection against SARS-CoV-2 after Vaccination and Previous Infection. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  131. MATUCHANSKY C
    Protection against SARS-CoV-2 after Vaccination and Previous Infection.
    N Engl J Med. 2022;386.
    PubMed    


  132. ALTARAWNEH HN, Chemaitelly H, Ayoub HH, Tang P, et al
    Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMoa2203965.
    PubMed     Abstract available


    May 2022
  133. GOLDBERG Y, Mandel M, Bar-On YM, Bodenheimer O, et al
    Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
    N Engl J Med. 2022 May 25. doi: 10.1056/NEJMoa2118946.
    PubMed     Abstract available


  134. ACCORSI EK, Britton A, Shang N, Fleming-Dutra KE, et al
    Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron.
    N Engl J Med. 2022 May 25. doi: 10.1056/NEJMc2203165.
    PubMed    


  135. BROWN PE, Fu SH, Bansal A, Newcombe L, et al
    Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults.
    N Engl J Med. 2022 May 18. doi: 10.1056/NEJMc2202879.
    PubMed    


  136. CREECH CB, Anderson E, Berthaud V, Yildirim I, et al
    Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
    N Engl J Med. 2022 May 11. doi: 10.1056/NEJMoa2203315.
    PubMed     Abstract available


  137. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Do We Need New Covid-19 Vaccines?
    N Engl J Med. 2022;386:e52.
    PubMed    


  138. HAGER KJ, Perez Marc G, Gobeil P, Diaz RS, et al
    Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2201300.
    PubMed     Abstract available


  139. GRAY G, Collie S, Goga A, Garrett N, et al
    Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMc2202061.
    PubMed    


  140. DAI L, Gao L, Tao L, Hadinegoro SR, et al
    Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2202261.
    PubMed     Abstract available


  141. NOHYNEK H, Wilder-Smith A
    Does the World Still Need New Covid-19 Vaccines?
    N Engl J Med. 2022 May 4. doi: 10.1056/NEJMe2204695.
    PubMed    


    April 2022
  142. MEISSNER HC
    Understanding Vaccine Safety and the Roles of the FDA and the CDC.
    N Engl J Med. 2022;386:1638-1645.
    PubMed    


  143. SIMOES EAF, Center KJ, Tita ATN, Swanson KA, et al
    Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
    N Engl J Med. 2022;386:1615-1626.
    PubMed     Abstract available


  144. RUBIN EJ, Baden LR, Bloom BR, Morrissey S, et al
    Audio Interview: Do the Tobacco Wars Offer Any Lessons for the Vaccine Wars?
    N Engl J Med. 2022;386:e48.
    PubMed    


  145. BAZELL R, Koh H, Bloom BR
    The Tobacco Wars' Lessons for the Vaccination Wars.
    N Engl J Med. 2022 Apr 13. doi: 10.1056/NEJMp2202618.
    PubMed    


  146. MAGEN O, Waxman JG, Makov-Assif M, Vered R, et al
    Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
    N Engl J Med. 2022 Apr 13. doi: 10.1056/NEJMoa2201688.
    PubMed     Abstract available


  147. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Do We Need a Fourth Dose of Covid Vaccine?
    N Engl J Med. 2022;386:e45.
    PubMed    


  148. YOON SK, Hegmann KT, Thiese MS, Burgess JL, et al
    Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers.
    N Engl J Med. 2022 Apr 6. doi: 10.1056/NEJMc2201821.
    PubMed    


  149. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
    Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
    N Engl J Med. 2022 Apr 5. doi: 10.1056/NEJMoa2201570.
    PubMed     Abstract available


    March 2022
  150. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Effectiveness of Covid-19 Vaccination in Children.
    N Engl J Med. 2022;386:e39.
    PubMed    


  151. KLEIN NP
    Added Benefit of Covid-19 Vaccination after Previous Infection.
    N Engl J Med. 2022;386:1278-1279.
    PubMed    


  152. PRICE AM, Olson SM, Newhams MM, Halasa NB, et al
    BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
    N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2202826.
    PubMed     Abstract available


  153. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19: Why We Publish What We Do.
    N Engl J Med. 2022;386:e38.
    PubMed    


  154. MOREIRA ED JR, Kitchin N, Xu X, Dychter SS, et al
    Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
    N Engl J Med. 2022 Mar 23. doi: 10.1056/NEJMoa2200674.
    PubMed     Abstract available


  155. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Can We Make More Effective Covid-19 Vaccines?
    N Engl J Med. 2022;386:e36.
    PubMed    


  156. REGEV-YOCHAY G, Gonen T, Gilboa M, Mandelboim M, et al
    Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.
    N Engl J Med. 2022 Mar 16. doi: 10.1056/NEJMc2202542.
    PubMed    


  157. ALONSO PL, O'Brien KL
    A Malaria Vaccine for Africa - An Important Step in a Century-Long Quest.
    N Engl J Med. 2022 Mar 12. doi: 10.1056/NEJMp2116591.
    PubMed    


  158. RUBIN EJ, Baden LR, Hunter D, Morrissey S, et al
    Audio Interview: Making Covid-19 Vaccines Available around the World.
    N Engl J Med. 2022;386:e31.
    PubMed    


  159. ABU-RADDAD LJ, Chemaitelly H, Ayoub HH, AlMukdad S, et al
    Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMoa2200797.
    PubMed     Abstract available


  160. MONTO AS
    The Future of SARS-CoV-2 Vaccination. Reply.
    N Engl J Med. 2022;386:899-900.
    PubMed    


  161. BACHMANN MF, Mohsen MO, Speiser DE
    The Future of SARS-CoV-2 Vaccination.
    N Engl J Med. 2022;386:899.
    PubMed    


  162. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Using Our Covid-19 Experience to Develop Vaccines More Quickly.
    N Engl J Med. 2022;386:e29.
    PubMed    


  163. ZHAO X, Li D, Ruan W, Chen Z, et al
    Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant.
    N Engl J Med. 2022;386:894-896.
    PubMed    


  164. WALTER EB, Talaat KR, Gurtman A
    More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  165. LEIBOWITZ R, Schurr E, Hirsch O
    More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  166. TAYTARD J, Prevost B, Corvol H
    More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  167. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
    Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
    N Engl J Med. 2022 Mar 2. doi: 10.1056/NEJMoa2119451.
    PubMed     Abstract available


  168. SAVILLE M, Cramer JP, Downham M, Hacker A, et al
    Delivering Pandemic Vaccines in 100 Days - What Will It Take?
    N Engl J Med. 2022 Mar 2. doi: 10.1056/NEJMp2202669.
    PubMed    


    February 2022
  169. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Understanding the Omicron Variant of SARS-CoV-2.
    N Engl J Med. 2022;386:e27.
    PubMed    


  170. HUNTER DJ, Abdool Karim SS, Baden LR, Farrar JJ, et al
    Addressing Vaccine Inequity - Covid-19 Vaccines as a Global Public Good.
    N Engl J Med. 2022 Feb 23. doi: 10.1056/NEJMe2202547.
    PubMed    


  171. MADHI SA, Kwatra G, Myers JE, Jassat W, et al
    Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.
    N Engl J Med. 2022 Feb 23. doi: 10.1056/NEJMoa2119658.
    PubMed     Abstract available


  172. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Antiviral against Covid-19.
    N Engl J Med. 2022;386:e25.
    PubMed    


  173. AHMAD A, Eze K, Noulin N, Horvathova V, et al
    EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
    N Engl J Med. 2022;386:655-666.
    PubMed     Abstract available


  174. HAMMERMAN A, Sergienko R, Friger M, Beckenstein T, et al
    Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19.
    N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2119497.
    PubMed     Abstract available


  175. HALL V, Foulkes S, Insalata F, Kirwan P, et al
    Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
    N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2118691.
    PubMed     Abstract available


  176. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 as an Endemic Disease.
    N Engl J Med. 2022;386:e21.
    PubMed    


  177. ARBEL R, Sergienko R, Hammerman A
    BNT162b2 Vaccine Booster and Covid-19 Mortality. Reply.
    N Engl J Med. 2022 Feb 9. pii: 10.1056/NEJMc2120044.
    PubMed    


  178. PILZ S
    BNT162b2 Vaccine Booster and Covid-19 Mortality.
    N Engl J Med. 2022 Feb 9. pii: 10.1056/NEJMc2120044.
    PubMed    


  179. ROHBAN T
    BNT162b2 Vaccine Booster and Covid-19 Mortality.
    N Engl J Med. 2022 Feb 9. pii: 10.1056/NEJMc2120044.
    PubMed    


  180. SADOFF J, Gray G, Vandebosch A, Cardenas V, et al
    Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
    N Engl J Med. 2022 Feb 9. doi: 10.1056/NEJMoa2117608.
    PubMed     Abstract available


  181. MAYR FB, Talisa VB, Shaikh O, Yende S, et al
    Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans.
    N Engl J Med. 2022 Feb 9. doi: 10.1056/NEJMc2200415.
    PubMed    



  182. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
    N Engl J Med. 2022;386:500.
    PubMed    


  183. MURPHY WJ, Longo DL
    Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination. Reply.
    N Engl J Med. 2022 Feb 2. pii: 10.1056/NEJMc2119443.
    PubMed    


  184. HARVILLE TO, Arthur JM
    Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    N Engl J Med. 2022 Feb 2. pii: 10.1056/NEJMc2119443.
    PubMed    


  185. DE MARIA A
    Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    N Engl J Med. 2022 Feb 2. pii: 10.1056/NEJMc2119443.
    PubMed    


    January 2022
  186. RUBIN EJ, Baden LR, Barocas JA, Morrissey S, et al
    Audio Interview: Addressing the Omicron Variant of SARS-CoV-2.
    N Engl J Med. 2022;386:e16.
    PubMed    


  187. PAJON R, Doria-Rose NA, Shen X, Schmidt SD, et al
    SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2119912.
    PubMed    


  188. MEVORACH D, Anis E, Cedar N, Hasin T, et al
    Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2116999.
    PubMed    


  189. ABU-RADDAD LJ, Chemaitelly H, Bertollini R
    Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2119432.
    PubMed    


  190. ATMAR RL, Lyke KE, Deming ME, Jackson LA, et al
    Homologous and Heterologous Covid-19 Booster Vaccinations.
    N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMoa2116414.
    PubMed     Abstract available


  191. RUBIN EJ, Baden LR, Fineberg HV, Morrissey S, et al
    Audio Interview: Crushing the Covid-19 Curve.
    N Engl J Med. 2022;386:e13.
    PubMed    


  192. SABLEROLLES RSG, Rietdijk WJR, Goorhuis A, Postma DF, et al
    Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    N Engl J Med. 2022 Jan 19. doi: 10.1056/NEJMoa2116747.
    PubMed     Abstract available


  193. WALTER EB, Talaat KR, Gurtman A
    BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  194. MINTZKER Y
    BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  195. FANG SF, Liu N, Du HW
    BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2022;386.
    PubMed    


  196. ABU-RADDAD LJ, Chemaitelly H, Bertollini R
    Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar.
    N Engl J Med. 2022 Jan 19. doi: 10.1056/NEJMc2117933.
    PubMed    


  197. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 Takeaways at Podcast 100.
    N Engl J Med. 2022;386:e11.
    PubMed    


  198. ROSSLER A, Riepler L, Bante D, von Laer D, et al
    SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMc2119236.
    PubMed    


  199. OLSON SM, Newhams MM, Halasa NB, Price AM, et al
    Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2117995.
    PubMed     Abstract available


  200. ANDREWS N, Tessier E, Stowe J, Gower C, et al
    Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2115481.
    PubMed     Abstract available


  201. EDWARDS KM
    Sparing of Severe Covid-19 in Vaccinated Adolescents.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMe2118471.
    PubMed    


  202. LIN DY, Gu Y, Wheeler B, Young H, et al
    Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.
    N Engl J Med. 2022 Jan 12. doi: 10.1056/NEJMoa2117128.
    PubMed     Abstract available


  203. EYRE DW, Taylor D, Purver M, Chapman D, et al
    Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants.
    N Engl J Med. 2022 Jan 5. doi: 10.1056/NEJMoa2116597.
    PubMed     Abstract available


  204. GONEN T, Lustig Y, Regev-Yochay G
    Covid-19 Infections in Vaccinated Health Care Workers. Reply.
    N Engl J Med. 2022;386.
    PubMed    


  205. RASTMANESH R
    Covid-19 Infections in Vaccinated Health Care Workers.
    N Engl J Med. 2022;386.
    PubMed    


    December 2021
  206. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Covid-19 Vaccination and the Omicron Variant.
    N Engl J Med. 2021;385:e102.
    PubMed    


  207. RITTENBERG E
    Trust, Faith, and Covid.
    N Engl J Med. 2021;385:2504-2505.
    PubMed    


  208. SCHMIDT F, Muecksch F, Weisblum Y, Da Silva J, et al
    Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
    N Engl J Med. 2021 Dec 30. doi: 10.1056/NEJMc2119641.
    PubMed    


  209. COLLIE S, Champion J, Moultrie H, Bekker LG, et al
    Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.
    N Engl J Med. 2021 Dec 29. doi: 10.1056/NEJMc2119270.
    PubMed    


  210. NEMET I, Kliker L, Lustig Y, Zuckerman N, et al
    Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
    N Engl J Med. 2021 Dec 29. doi: 10.1056/NEJMc2119358.
    PubMed    


  211. MCGREW S, Taylor HA
    Adolescents, Parents, and Covid-19 Vaccination - Who Should Decide?
    N Engl J Med. 2021 Dec 29. doi: 10.1056/NEJMp2116771.
    PubMed    


  212. KISSLER SM, Fauver JR, Mack C, Tai CG, et al
    Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons.
    N Engl J Med. 2021;385:2489-2491.
    PubMed    


  213. FOXWORTH R, Redvers N, Moreno MA, Lopez-Carmen VA, et al
    Covid-19 Vaccination in American Indians and Alaska Natives - Lessons from Effective Community Responses.
    N Engl J Med. 2021;385:2403-2406.
    PubMed    


  214. MUHSEN K, Maimon N, Mizrahi A, Varticovschi B, et al
    Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel.
    N Engl J Med. 2021 Dec 22. doi: 10.1056/NEJMc2117385.
    PubMed    


  215. LACY J, Pavord S, Brown KE
    VITT and Second Doses of Covid-19 Vaccine.
    N Engl J Med. 2021 Dec 22. doi: 10.1056/NEJMc2118507.
    PubMed    


  216. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?
    N Engl J Med. 2021;385:e100.
    PubMed    


  217. MORENS DM, Taubenberger JK, Fauci AS
    Universal Coronavirus Vaccines - An Urgent Need.
    N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMp2118468.
    PubMed    


  218. HORTON LE, Abeles SR, Torriani FJ
    SARS-CoV-2 Infection in Vaccinated Health Care Workers. Reply.
    N Engl J Med. 2021 Dec 15. pii: 10.1056/NEJMc2117119.
    PubMed    


  219. LILLERI D, Marena C, Baldanti F
    SARS-CoV-2 Infection in Vaccinated Health Care Workers.
    N Engl J Med. 2021 Dec 15. pii: 10.1056/NEJMc2117119.
    PubMed    


  220. DUNKLE LM, Kotloff KL, Gay CL, Anez G, et al
    Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
    N Engl J Med. 2021 Dec 15. doi: 10.1056/NEJMoa2116185.
    PubMed     Abstract available


  221. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Waning Immunity against SARS-CoV-2.
    N Engl J Med. 2021;385:e99.
    PubMed    


  222. ARBEL R, Hammerman A, Sergienko R, Friger M, et al
    BNT162b2 Vaccine Booster and Mortality Due to Covid-19.
    N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMoa2115624.
    PubMed     Abstract available


  223. MCGARRY BE, Barnett ML, Grabowski DC, Gandhi AD, et al
    Nursing Home Staff Vaccination and Covid-19 Outcomes.
    N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMc2115674.
    PubMed    


  224. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
    Protection against Covid-19 by BNT162b2 Booster across Age Groups.
    N Engl J Med. 2021 Dec 8. doi: 10.1056/NEJMoa2115926.
    PubMed     Abstract available


  225. CAFORIO ALP
    Receipt of mRNA Vaccine against Covid-19 and Myocarditis.
    N Engl J Med. 2021;385:2189-2190.
    PubMed    


  226. RUBIN EJ, Baden LR, Abdool Karim SS, Morrissey S, et al
    Audio Interview: The Omicron Variant of SARS-CoV-2.
    N Engl J Med. 2021;385:e96.
    PubMed    


  227. RUBIN EJ, Longo DL
    Covid-19 mRNA Vaccines - Six of One, Half a Dozen of the Other.
    N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMe2117446.
    PubMed    


  228. ROSENBERG ES, Dorabawila V, Easton D, Bauer UE, et al
    Covid-19 Vaccine Effectiveness in New York State.
    N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2116063.
    PubMed     Abstract available


  229. DICKERMAN BA, Gerlovin H, Madenci AL, Kurgansky KE, et al
    Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
    N Engl J Med. 2021 Dec 1. doi: 10.1056/NEJMoa2115463.
    PubMed     Abstract available


    November 2021
  230. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: What's Gone Right in Our Battle against Covid-19.
    N Engl J Med. 2021;385:e95.
    PubMed    


  231. MURPHY WJ, Longo DL
    A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    N Engl J Med. 2021 Nov 24. doi: 10.1056/NEJMcibr2113694.
    PubMed    


  232. RUBIN EJ, Baden LR, Mello MM, Morrissey S, et al
    Audio Interview: The Legal Basis for Covid-19 Restrictions and Mandates.
    N Engl J Med. 2021;385:e88.
    PubMed    


  233. RUBIN EJ, Baden LR, Grinsztejn B, Morrissey S, et al
    Audio Interview: Covid-19 in Brazil and New Evidence for Vaccinating Younger Children.
    N Engl J Med. 2021;385:e79.
    PubMed    


  234. LOPEZ BERNAL J, Gower C, Andrews N
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  235. EMANI VR, Reddy R, Goswami S
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  236. LINSENMEYER K, Gupta K, Charness ME
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  237. TORGOVNICK J
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Nov 10. pii: 10.1056/NEJMc2113090.
    PubMed    


  238. WALTER EB, Talaat KR, Sabharwal C, Gurtman A, et al
    Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
    N Engl J Med. 2021 Nov 9. doi: 10.1056/NEJMoa2116298.
    PubMed     Abstract available


  239. MONTO AS
    The Future of SARS-CoV-2 Vaccination - Lessons from Influenza.
    N Engl J Med. 2021 Nov 6. doi: 10.1056/NEJMp2113403.
    PubMed    


  240. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Do We Have the Tools to End the Covid-19 Pandemic?
    N Engl J Med. 2021;385:e78.
    PubMed    


  241. SCHONBORN L, Thiele T, Kaderali L, Greinacher A, et al
    Decline in Pathogenic Antibodies over Time in VITT.
    N Engl J Med. 2021;385:1815-1816.
    PubMed    


  242. SCULLY M
    VITT after ChAdOx1 nCoV-19 Vaccination. Reply.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  243. GREINACHER A, Schonborn L, Thiele T
    VITT after ChAdOx1 nCoV-19 Vaccination. Reply.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  244. WEBER C, von Hundelshausen P, Siess W
    VITT after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  245. SANTIN AD
    VITT after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.
    PubMed    


  246. URIU K, Kimura I, Shirakawa K, Takaori-Kondo A, et al
    Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
    N Engl J Med. 2021 Nov 3. doi: 10.1056/NEJMc2114706.
    PubMed    


    October 2021
  247. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Monoclonal Antibody for Covid-19 and Potential Vaccination for Children.
    N Engl J Med. 2021;385:e74.
    PubMed    


  248. ASKENASE PW
    Rare Skin Reactions after mRNA Vaccination, Similar to Jones-Mote Basophil Responses.
    N Engl J Med. 2021;385:1720-1721.
    PubMed    


  249. GOLDBERG Y, Mandel M, Bar-On YM, Bodenheimer O, et al
    Waning Immunity after the BNT162b2 Vaccine in Israel.
    N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMoa2114228.
    PubMed     Abstract available


  250. DAGAN N, Barda N, Balicer RD
    Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex.
    N Engl J Med. 2021 Oct 27. doi: 10.1056/NEJMc2115045.
    PubMed    


  251. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Look at Covid-19 Vaccine Boosters.
    N Engl J Med. 2021;385:e72.
    PubMed    


  252. MAGNUS MC, Gjessing HK, Eide HN, Wilcox AJ, et al
    Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114466.
    PubMed    


  253. CHIN ET, Leidner D, Zhang Y, Long E, et al
    Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114089.
    PubMed    


  254. SHEIKH A, Robertson C, Taylor B
    BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2113864.
    PubMed    


  255. REIS BY, Barda N, Leshchinsky M, Kepten E, et al
    Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents.
    N Engl J Med. 2021 Oct 20. doi: 10.1056/NEJMc2114290.
    PubMed    


  256. COLLIER AY, Yu J, McMahan K, Liu J, et al
    Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines.
    N Engl J Med. 2021 Oct 15. doi: 10.1056/NEJMc2115596.
    PubMed    


  257. NOLAN T, Fortanier AC, Leav B, Poder A, et al
    Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
    N Engl J Med. 2021;385:1485-1495.
    PubMed     Abstract available


  258. RUBIN EJ, Baden LR, Wu KJ, Morrissey S, et al
    Audio Interview: Reporting on Covid-19.
    N Engl J Med. 2021;385:e66.
    PubMed    


  259. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Are Covid-19 Vaccine Boosters Necessary?
    N Engl J Med. 2021;385:e63.
    PubMed    


  260. WITBERG G, Barda N, Hoss S, Richter I, et al
    Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2110737.
    PubMed     Abstract available


  261. MEVORACH D, Anis E, Cedar N, Bromberg M, et al
    Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2109730.
    PubMed     Abstract available


  262. CHEMAITELLY H, Tang P, Hasan MR, AlMukdad S, et al
    Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2114114.
    PubMed     Abstract available


  263. LEVIN EG, Lustig Y, Cohen C, Fluss R, et al
    Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.
    N Engl J Med. 2021 Oct 6. doi: 10.1056/NEJMoa2114583.
    PubMed     Abstract available


  264. THOMPSON MG, Grant L, Meece J
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. Reply.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


  265. ZHANG C, Yin G
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


  266. SCHOOLEY RT
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


  267. SANTACATTERINA M, Sanders JW, Weintraub WS
    Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2021 Oct 6. pii: 10.1056/NEJMc2113575.
    PubMed    


    September 2021
  268. RUBIN EJ, Baden LR, Tofel R, Morrissey S, et al
    Audio Interview: Covid-19 and the Media.
    N Engl J Med. 2021;385:e59.
    PubMed    


  269. FALSEY AR, Sobieszczyk ME, Hirsch I, Sproule S, et al
    Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
    N Engl J Med. 2021 Sep 29. doi: 10.1056/NEJMoa2105290.
    PubMed     Abstract available


  270. AMIT S, Gonen T, Regev-Yochay G
    Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. Reply.
    N Engl J Med. 2021;385.
    PubMed    


  271. JUNG J, Sung H, Kim SH
    Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
    N Engl J Med. 2021;385.
    PubMed    


  272. STUART LM
    In Gratitude for mRNA Vaccines.
    N Engl J Med. 2021 Sep 24. doi: 10.1056/NEJMcibr2111445.
    PubMed    


  273. STOKKE JL, Szymanski LJ, Bankamp B, Pratt F, et al
    MMR Vaccine-Associated Disseminated Measles in an Immunocompromised Adolescent.
    N Engl J Med. 2021;385:1246-1248.
    PubMed    


  274. LIANG TJ, Feld JJ, Cox AL, Rice CM, et al
    Controlled Human Infection Model - Fast Track to HCV Vaccine?
    N Engl J Med. 2021;385:1235-1240.
    PubMed    


  275. ZAUCHE LH, Wallace B, Smoots AN, Olson CK, et al
    Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion.
    N Engl J Med. 2021 Sep 8. doi: 10.1056/NEJMc2113891.
    PubMed    


    August 2021
  276. TAN CW, Chia WN, Young BE, Zhu F, et al
    Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors.
    N Engl J Med. 2021 Aug 18. doi: 10.1056/NEJMoa2108453.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.